| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neurosurgery | 26 | 2024 | 76 | 7.780 |
Why?
|
| Neurosurgical Procedures | 45 | 2026 | 231 | 6.270 |
Why?
|
| Intracranial Aneurysm | 15 | 2026 | 63 | 6.100 |
Why?
|
| Radiosurgery | 18 | 2025 | 84 | 5.660 |
Why?
|
| Subarachnoid Hemorrhage | 18 | 2025 | 59 | 4.460 |
Why?
|
| Intracranial Arteriovenous Malformations | 9 | 2024 | 16 | 4.360 |
Why?
|
| Pituitary Neoplasms | 10 | 2025 | 50 | 3.580 |
Why?
|
| Neuroma, Acoustic | 12 | 2022 | 23 | 3.320 |
Why?
|
| Humans | 168 | 2026 | 28884 | 3.050 |
Why?
|
| Internship and Residency | 13 | 2022 | 250 | 2.850 |
Why?
|
| Adenoma | 7 | 2023 | 61 | 2.640 |
Why?
|
| Microsurgery | 14 | 2026 | 50 | 2.540 |
Why?
|
| Cerebral Revascularization | 5 | 2024 | 11 | 2.180 |
Why?
|
| Brain Neoplasms | 8 | 2025 | 313 | 2.110 |
Why?
|
| Social Media | 6 | 2022 | 67 | 1.790 |
Why?
|
| Middle Cerebral Artery | 3 | 2026 | 54 | 1.780 |
Why?
|
| Middle Aged | 55 | 2025 | 7416 | 1.660 |
Why?
|
| Vein of Galen Malformations | 2 | 2023 | 3 | 1.620 |
Why?
|
| Male | 68 | 2025 | 13934 | 1.600 |
Why?
|
| Retrospective Studies | 40 | 2025 | 2635 | 1.590 |
Why?
|
| Treatment Outcome | 34 | 2025 | 2426 | 1.530 |
Why?
|
| Postoperative Complications | 10 | 2023 | 634 | 1.490 |
Why?
|
| Craniotomy | 9 | 2023 | 61 | 1.450 |
Why?
|
| Vasospasm, Intracranial | 4 | 2025 | 18 | 1.450 |
Why?
|
| Central Nervous System Neoplasms | 3 | 2026 | 16 | 1.330 |
Why?
|
| Odontoid Process | 4 | 2021 | 13 | 1.310 |
Why?
|
| Neurilemmoma | 5 | 2019 | 13 | 1.300 |
Why?
|
| Female | 57 | 2026 | 15634 | 1.300 |
Why?
|
| Adult | 39 | 2026 | 8030 | 1.300 |
Why?
|
| Hypopituitarism | 2 | 2021 | 5 | 1.260 |
Why?
|
| Meningioma | 5 | 2019 | 79 | 1.240 |
Why?
|
| Meta-Analysis as Topic | 3 | 2024 | 33 | 1.190 |
Why?
|
| Intraoperative Complications | 2 | 2021 | 47 | 1.190 |
Why?
|
| Craniopharyngioma | 2 | 2025 | 16 | 1.140 |
Why?
|
| Meningitis | 2 | 2026 | 12 | 1.130 |
Why?
|
| Oligodendroglioma | 2 | 2025 | 13 | 1.110 |
Why?
|
| Spinal Fractures | 3 | 2017 | 44 | 1.100 |
Why?
|
| Skull Base Neoplasms | 5 | 2022 | 22 | 1.060 |
Why?
|
| Periodicals as Topic | 4 | 2022 | 53 | 1.050 |
Why?
|
| Central Nervous System Vascular Malformations | 3 | 2025 | 5 | 1.050 |
Why?
|
| General Surgery | 2 | 2020 | 63 | 1.050 |
Why?
|
| Relative Biological Effectiveness | 3 | 2021 | 7 | 1.030 |
Why?
|
| Foreign Medical Graduates | 3 | 2021 | 10 | 1.020 |
Why?
|
| Meningeal Neoplasms | 3 | 2019 | 73 | 1.010 |
Why?
|
| Cerebellopontine Angle | 5 | 2019 | 8 | 1.010 |
Why?
|
| Arteriovenous Malformations | 2 | 2023 | 16 | 0.990 |
Why?
|
| Orbit | 1 | 2026 | 12 | 0.970 |
Why?
|
| Brain Ischemia | 6 | 2023 | 87 | 0.960 |
Why?
|
| Basilar Artery | 2 | 2022 | 7 | 0.950 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2025 | 33 | 0.940 |
Why?
|
| Nimodipine | 1 | 2025 | 7 | 0.930 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2026 | 81 | 0.910 |
Why?
|
| Calcium Channel Blockers | 1 | 2025 | 41 | 0.910 |
Why?
|
| Students, Medical | 4 | 2022 | 102 | 0.910 |
Why?
|
| Aneurysm | 2 | 2022 | 25 | 0.900 |
Why?
|
| Bibliometrics | 3 | 2022 | 20 | 0.900 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2025 | 166 | 0.890 |
Why?
|
| Magnetic Resonance Imaging | 14 | 2026 | 841 | 0.890 |
Why?
|
| Skull Base | 6 | 2022 | 35 | 0.880 |
Why?
|
| Aged | 29 | 2025 | 5599 | 0.880 |
Why?
|
| Carotid Artery, Internal | 3 | 2022 | 19 | 0.870 |
Why?
|
| Hemangioendothelioma, Epithelioid | 1 | 2024 | 5 | 0.860 |
Why?
|
| Cerebrovascular Disorders | 1 | 2024 | 46 | 0.850 |
Why?
|
| Intracranial Hypotension | 3 | 2021 | 6 | 0.840 |
Why?
|
| Mesencephalon | 2 | 2023 | 7 | 0.830 |
Why?
|
| Arteriovenous Fistula | 2 | 2021 | 16 | 0.830 |
Why?
|
| Neurosurgeons | 7 | 2024 | 22 | 0.820 |
Why?
|
| Cerebellar Neoplasms | 4 | 2019 | 30 | 0.810 |
Why?
|
| Vascular Grafting | 1 | 2023 | 11 | 0.800 |
Why?
|
| Leadership | 2 | 2020 | 55 | 0.780 |
Why?
|
| Endarterectomy, Carotid | 1 | 2022 | 11 | 0.740 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 4 | 2023 | 16 | 0.710 |
Why?
|
| Aged, 80 and over | 17 | 2025 | 2065 | 0.710 |
Why?
|
| ACTH-Secreting Pituitary Adenoma | 1 | 2021 | 2 | 0.710 |
Why?
|
| Hemangioblastoma | 2 | 2022 | 12 | 0.710 |
Why?
|
| Cranial Nerve Neoplasms | 3 | 2019 | 7 | 0.690 |
Why?
|
| Tranexamic Acid | 1 | 2021 | 16 | 0.690 |
Why?
|
| Peer Review | 1 | 2021 | 15 | 0.680 |
Why?
|
| Antifibrinolytic Agents | 1 | 2021 | 26 | 0.680 |
Why?
|
| Coronavirus | 1 | 2020 | 2 | 0.680 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2019 | 63 | 0.680 |
Why?
|
| Acromegaly | 1 | 2020 | 3 | 0.670 |
Why?
|
| Surgeons | 2 | 2020 | 50 | 0.670 |
Why?
|
| Interpersonal Relations | 2 | 2020 | 65 | 0.660 |
Why?
|
| Registries | 4 | 2024 | 397 | 0.660 |
Why?
|
| Hydrocephalus | 5 | 2022 | 55 | 0.660 |
Why?
|
| Career Choice | 3 | 2022 | 53 | 0.660 |
Why?
|
| Trochlear Nerve Diseases | 2 | 2017 | 5 | 0.660 |
Why?
|
| Follow-Up Studies | 12 | 2021 | 1032 | 0.650 |
Why?
|
| Cerebellar Diseases | 2 | 2019 | 4 | 0.650 |
Why?
|
| Diagnosis, Differential | 9 | 2026 | 379 | 0.640 |
Why?
|
| Pandemics | 2 | 2024 | 202 | 0.640 |
Why?
|
| Social Behavior | 1 | 2020 | 54 | 0.640 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2020 | 347 | 0.640 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 49 | 0.630 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 53 | 0.630 |
Why?
|
| Research | 1 | 2020 | 93 | 0.630 |
Why?
|
| Cooperative Behavior | 1 | 2020 | 78 | 0.630 |
Why?
|
| Endoscopy | 3 | 2023 | 57 | 0.620 |
Why?
|
| Hemorrhage | 1 | 2021 | 266 | 0.610 |
Why?
|
| Cerebral Arteries | 1 | 2019 | 33 | 0.610 |
Why?
|
| Spinal Cord Neoplasms | 3 | 2025 | 40 | 0.590 |
Why?
|
| Vertebral Artery | 4 | 2024 | 16 | 0.590 |
Why?
|
| Cohort Studies | 10 | 2022 | 897 | 0.570 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2020 | 301 | 0.570 |
Why?
|
| Curriculum | 2 | 2019 | 304 | 0.550 |
Why?
|
| Adventitia | 1 | 2017 | 2 | 0.540 |
Why?
|
| Clinical Competence | 4 | 2022 | 235 | 0.530 |
Why?
|
| Trochlear Nerve | 1 | 2017 | 1 | 0.520 |
Why?
|
| Hematoma, Subdural, Spinal | 1 | 2017 | 1 | 0.520 |
Why?
|
| Nelson Syndrome | 1 | 2017 | 1 | 0.520 |
Why?
|
| Embolization, Therapeutic | 3 | 2022 | 48 | 0.520 |
Why?
|
| Adrenalectomy | 1 | 2017 | 13 | 0.520 |
Why?
|
| Laminectomy | 1 | 2017 | 31 | 0.510 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2016 | 26 | 0.500 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 2016 | 4 | 0.490 |
Why?
|
| Angiography, Digital Subtraction | 3 | 2025 | 19 | 0.490 |
Why?
|
| Adolescent | 11 | 2025 | 3197 | 0.480 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2015 | 2 | 0.470 |
Why?
|
| Cavernous Sinus | 3 | 2022 | 5 | 0.470 |
Why?
|
| Specialties, Surgical | 1 | 2015 | 6 | 0.470 |
Why?
|
| Child | 7 | 2023 | 2291 | 0.460 |
Why?
|
| Mentors | 1 | 2015 | 39 | 0.460 |
Why?
|
| Self Efficacy | 1 | 2016 | 80 | 0.460 |
Why?
|
| Prospective Studies | 9 | 2024 | 1280 | 0.450 |
Why?
|
| Young Adult | 13 | 2025 | 2839 | 0.450 |
Why?
|
| Cerebellum | 4 | 2024 | 41 | 0.450 |
Why?
|
| Head and Neck Neoplasms | 1 | 2016 | 93 | 0.440 |
Why?
|
| Aneurysm, Ruptured | 3 | 2023 | 17 | 0.400 |
Why?
|
| Epidermal Cyst | 2 | 2025 | 5 | 0.390 |
Why?
|
| Hemangioma, Cavernous, Central Nervous System | 2 | 2022 | 4 | 0.390 |
Why?
|
| Surveys and Questionnaires | 4 | 2022 | 1002 | 0.390 |
Why?
|
| Dura Mater | 2 | 2022 | 11 | 0.380 |
Why?
|
| Sarcoma | 2 | 2024 | 29 | 0.370 |
Why?
|
| Cadaver | 2 | 2026 | 61 | 0.370 |
Why?
|
| Spinal Neoplasms | 2 | 2024 | 40 | 0.370 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2021 | 194 | 0.360 |
Why?
|
| Cerebral Infarction | 5 | 2023 | 26 | 0.360 |
Why?
|
| Liver | 5 | 2015 | 471 | 0.350 |
Why?
|
| Incidence | 6 | 2022 | 572 | 0.350 |
Why?
|
| Drainage | 5 | 2023 | 45 | 0.340 |
Why?
|
| Reading | 2 | 2022 | 19 | 0.340 |
Why?
|
| Societies, Medical | 2 | 2021 | 93 | 0.330 |
Why?
|
| Job Application | 2 | 2020 | 3 | 0.330 |
Why?
|
| Neuroendoscopy | 2 | 2021 | 14 | 0.330 |
Why?
|
| Neoplasm Grading | 3 | 2020 | 105 | 0.330 |
Why?
|
| Hydrocephalus, Normal Pressure | 2 | 2022 | 3 | 0.320 |
Why?
|
| Educational Measurement | 2 | 2021 | 131 | 0.320 |
Why?
|
| Decompression, Surgical | 2 | 2024 | 81 | 0.320 |
Why?
|
| Hearing Loss | 2 | 2020 | 39 | 0.310 |
Why?
|
| Cerebrospinal Fluid Rhinorrhea | 2 | 2021 | 5 | 0.300 |
Why?
|
| Radiometry | 2 | 2021 | 45 | 0.300 |
Why?
|
| Microvascular Decompression Surgery | 3 | 2018 | 7 | 0.300 |
Why?
|
| Communication | 2 | 2021 | 182 | 0.300 |
Why?
|
| Surgical Instruments | 3 | 2023 | 15 | 0.300 |
Why?
|
| Cerebral Ventricle Neoplasms | 2 | 2020 | 8 | 0.300 |
Why?
|
| Ependymoma | 2 | 2019 | 12 | 0.290 |
Why?
|
| Cerebral Angiography | 3 | 2025 | 38 | 0.290 |
Why?
|
| Hypertrophy | 2 | 2026 | 46 | 0.280 |
Why?
|
| Prognosis | 6 | 2023 | 811 | 0.280 |
Why?
|
| Lung Neoplasms | 2 | 2024 | 360 | 0.280 |
Why?
|
| Indocyanine Green | 2 | 2025 | 16 | 0.280 |
Why?
|
| Spinal Cord Injuries | 2 | 2020 | 69 | 0.270 |
Why?
|
| Glioblastoma | 2 | 2019 | 109 | 0.270 |
Why?
|
| United States | 8 | 2024 | 2225 | 0.270 |
Why?
|
| Skull | 2 | 2025 | 41 | 0.260 |
Why?
|
| Dendritic Cells | 3 | 2013 | 143 | 0.260 |
Why?
|
| Vertebrobasilar Insufficiency | 2 | 2017 | 4 | 0.260 |
Why?
|
| Venous Thrombosis | 2 | 2018 | 98 | 0.250 |
Why?
|
| Neuronavigation | 1 | 2026 | 13 | 0.240 |
Why?
|
| Anterior Cerebral Artery | 2 | 2023 | 3 | 0.240 |
Why?
|
| Printing, Three-Dimensional | 2 | 2023 | 31 | 0.240 |
Why?
|
| Cerebrospinal Fluid Leak | 3 | 2021 | 14 | 0.240 |
Why?
|
| Neoplasm Proteins | 2 | 2019 | 123 | 0.240 |
Why?
|
| Risk Factors | 8 | 2024 | 2127 | 0.230 |
Why?
|
| Education, Medical, Graduate | 3 | 2022 | 117 | 0.230 |
Why?
|
| Quality Improvement | 2 | 2023 | 124 | 0.220 |
Why?
|
| Education, Medical, Undergraduate | 2 | 2016 | 64 | 0.220 |
Why?
|
| Ventriculostomy | 3 | 2023 | 9 | 0.220 |
Why?
|
| Natural Orifice Endoscopic Surgery | 2 | 2021 | 9 | 0.210 |
Why?
|
| Stroke | 2 | 2018 | 261 | 0.210 |
Why?
|
| Thoracic Vertebrae | 1 | 2024 | 70 | 0.210 |
Why?
|
| Proportional Hazards Models | 3 | 2021 | 226 | 0.210 |
Why?
|
| Machine Learning | 1 | 2024 | 96 | 0.200 |
Why?
|
| Brain Edema | 1 | 2023 | 21 | 0.200 |
Why?
|
| Germinoma | 1 | 2023 | 4 | 0.200 |
Why?
|
| Ossification, Heterotopic | 1 | 2023 | 7 | 0.200 |
Why?
|
| Teratoma | 1 | 2023 | 17 | 0.200 |
Why?
|
| Intracranial Hemorrhages | 2 | 2020 | 32 | 0.200 |
Why?
|
| Spine | 2 | 2021 | 63 | 0.200 |
Why?
|
| Hemangioma, Cavernous | 1 | 2022 | 3 | 0.190 |
Why?
|
| Temporal Bone | 1 | 2023 | 30 | 0.190 |
Why?
|
| Cranial Nerves | 1 | 2022 | 6 | 0.190 |
Why?
|
| Reoperation | 3 | 2019 | 153 | 0.190 |
Why?
|
| Facial Nerve | 2 | 2022 | 6 | 0.190 |
Why?
|
| Intracranial Pressure | 1 | 2022 | 12 | 0.190 |
Why?
|
| von Hippel-Lindau Disease | 1 | 2022 | 9 | 0.190 |
Why?
|
| Pituitary Hormones | 1 | 2022 | 4 | 0.190 |
Why?
|
| Medulla Oblongata | 1 | 2022 | 12 | 0.190 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2024 | 404 | 0.190 |
Why?
|
| Prolactin | 1 | 2022 | 16 | 0.190 |
Why?
|
| Infant | 2 | 2023 | 1025 | 0.190 |
Why?
|
| Child, Preschool | 3 | 2021 | 1173 | 0.190 |
Why?
|
| Cysts | 1 | 2022 | 23 | 0.190 |
Why?
|
| Virtual Reality | 1 | 2022 | 11 | 0.180 |
Why?
|
| Pulmonary Embolism | 1 | 2023 | 126 | 0.180 |
Why?
|
| Neurodegenerative Diseases | 1 | 2022 | 25 | 0.180 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2022 | 68 | 0.180 |
Why?
|
| Temporal Muscle | 1 | 2021 | 2 | 0.180 |
Why?
|
| Editorial Policies | 1 | 2021 | 7 | 0.180 |
Why?
|
| Carotid Arteries | 1 | 2022 | 54 | 0.180 |
Why?
|
| Biomedical Technology | 1 | 2021 | 10 | 0.180 |
Why?
|
| Internationality | 1 | 2021 | 31 | 0.180 |
Why?
|
| Mutation | 1 | 2025 | 867 | 0.180 |
Why?
|
| Arteries | 1 | 2022 | 66 | 0.180 |
Why?
|
| Vascular Surgical Procedures | 1 | 2022 | 55 | 0.180 |
Why?
|
| Fistula | 1 | 2021 | 17 | 0.180 |
Why?
|
| Frailty | 1 | 2021 | 24 | 0.170 |
Why?
|
| Chondrosarcoma | 1 | 2021 | 6 | 0.170 |
Why?
|
| Sphenoid Bone | 2 | 2021 | 8 | 0.170 |
Why?
|
| Pinealoma | 1 | 2021 | 4 | 0.170 |
Why?
|
| Depressive Disorder, Major | 1 | 2022 | 127 | 0.170 |
Why?
|
| Sialadenitis | 1 | 2021 | 16 | 0.170 |
Why?
|
| Trigeminal Neuralgia | 2 | 2019 | 13 | 0.170 |
Why?
|
| Growth Hormone-Secreting Pituitary Adenoma | 1 | 2020 | 1 | 0.170 |
Why?
|
| Retirement | 1 | 2020 | 11 | 0.170 |
Why?
|
| Problem Solving | 1 | 2020 | 28 | 0.170 |
Why?
|
| Organizational Innovation | 1 | 2020 | 20 | 0.170 |
Why?
|
| Hemangiopericytoma | 1 | 2020 | 3 | 0.170 |
Why?
|
| Achromobacter denitrificans | 1 | 2020 | 2 | 0.160 |
Why?
|
| Chlorhexidine | 1 | 2020 | 7 | 0.160 |
Why?
|
| Solitary Fibrous Tumors | 1 | 2020 | 3 | 0.160 |
Why?
|
| Academies and Institutes | 1 | 2020 | 16 | 0.160 |
Why?
|
| Hematoma, Subdural, Intracranial | 1 | 2020 | 1 | 0.160 |
Why?
|
| Hematoma, Subdural, Acute | 1 | 2020 | 2 | 0.160 |
Why?
|
| Betacoronavirus | 1 | 2020 | 39 | 0.160 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2020 | 26 | 0.160 |
Why?
|
| Toes | 1 | 2020 | 3 | 0.160 |
Why?
|
| Jugular Veins | 2 | 2017 | 13 | 0.160 |
Why?
|
| Hematoma, Subdural, Chronic | 1 | 2020 | 8 | 0.160 |
Why?
|
| Metastasectomy | 1 | 2020 | 6 | 0.160 |
Why?
|
| Colloid Cysts | 1 | 2020 | 2 | 0.160 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2020 | 10 | 0.160 |
Why?
|
| Eosinophilia | 1 | 2020 | 8 | 0.160 |
Why?
|
| Subdural Effusion | 1 | 2019 | 2 | 0.160 |
Why?
|
| Publications | 1 | 2020 | 24 | 0.160 |
Why?
|
| Decompressive Craniectomy | 1 | 2019 | 6 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2019 | 27 | 0.160 |
Why?
|
| Accreditation | 1 | 2020 | 36 | 0.160 |
Why?
|
| Vertebral Artery Dissection | 1 | 2019 | 4 | 0.160 |
Why?
|
| Mental Disorders | 1 | 2021 | 114 | 0.160 |
Why?
|
| Rupture | 1 | 2019 | 12 | 0.160 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2019 | 20 | 0.160 |
Why?
|
| Eisenmenger Complex | 1 | 2019 | 2 | 0.160 |
Why?
|
| Neurofibromatosis 2 | 1 | 2019 | 3 | 0.150 |
Why?
|
| Neuroimaging | 1 | 2019 | 88 | 0.150 |
Why?
|
| Carotid Artery Injuries | 1 | 2019 | 12 | 0.150 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2019 | 5 | 0.150 |
Why?
|
| Frontal Lobe | 2 | 2017 | 43 | 0.150 |
Why?
|
| Hypotension | 1 | 2019 | 20 | 0.150 |
Why?
|
| Central Nervous System Cysts | 1 | 2019 | 4 | 0.150 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2019 | 46 | 0.150 |
Why?
|
| Trigeminal Ganglion | 1 | 2019 | 2 | 0.150 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2019 | 22 | 0.150 |
Why?
|
| Arteriovenous Anastomosis | 1 | 2019 | 1 | 0.150 |
Why?
|
| Anticoagulants | 2 | 2023 | 297 | 0.150 |
Why?
|
| Learning | 1 | 2020 | 100 | 0.150 |
Why?
|
| Ear Neoplasms | 1 | 2018 | 4 | 0.150 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2018 | 3 | 0.150 |
Why?
|
| Aneurysm, Dissecting | 1 | 2019 | 12 | 0.150 |
Why?
|
| Hypertension, Pulmonary | 1 | 2019 | 34 | 0.150 |
Why?
|
| Patient Readmission | 1 | 2020 | 108 | 0.150 |
Why?
|
| Brain | 3 | 2022 | 770 | 0.150 |
Why?
|
| Bevacizumab | 1 | 2019 | 106 | 0.150 |
Why?
|
| Glossopharyngeal Nerve | 1 | 2018 | 1 | 0.150 |
Why?
|
| Ear, Inner | 1 | 2018 | 13 | 0.150 |
Why?
|
| Glossopharyngeal Nerve Diseases | 1 | 2018 | 2 | 0.150 |
Why?
|
| Herpes Zoster Oticus | 1 | 2018 | 1 | 0.150 |
Why?
|
| Apoptosis | 4 | 2015 | 780 | 0.140 |
Why?
|
| Thrombectomy | 1 | 2018 | 30 | 0.140 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2019 | 108 | 0.140 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2019 | 79 | 0.140 |
Why?
|
| Glioma | 1 | 2019 | 122 | 0.140 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 164 | 0.140 |
Why?
|
| Physician's Role | 1 | 2018 | 29 | 0.140 |
Why?
|
| Peroneal Nerve | 1 | 2018 | 3 | 0.140 |
Why?
|
| Heart Defects, Congenital | 1 | 2019 | 95 | 0.140 |
Why?
|
| Ganglion Cysts | 1 | 2018 | 8 | 0.140 |
Why?
|
| Plasmacytoma | 1 | 2017 | 5 | 0.140 |
Why?
|
| Kidney Neoplasms | 1 | 2019 | 103 | 0.140 |
Why?
|
| Cranial Nerve Diseases | 1 | 2017 | 10 | 0.140 |
Why?
|
| Self Expandable Metallic Stents | 1 | 2017 | 2 | 0.140 |
Why?
|
| Knee Joint | 1 | 2018 | 43 | 0.140 |
Why?
|
| Lateral Ventricles | 1 | 2017 | 8 | 0.140 |
Why?
|
| Stress, Psychological | 1 | 2020 | 233 | 0.140 |
Why?
|
| Disease Models, Animal | 3 | 2019 | 1508 | 0.140 |
Why?
|
| Disease Management | 1 | 2018 | 91 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2020 | 481 | 0.140 |
Why?
|
| Otologic Surgical Procedures | 1 | 2017 | 4 | 0.130 |
Why?
|
| Histology | 1 | 2017 | 7 | 0.130 |
Why?
|
| Subarachnoid Space | 1 | 2017 | 3 | 0.130 |
Why?
|
| World Health Organization | 1 | 2017 | 13 | 0.130 |
Why?
|
| Pituitary ACTH Hypersecretion | 1 | 2017 | 3 | 0.130 |
Why?
|
| Subarachnoid Hemorrhage, Traumatic | 1 | 2017 | 2 | 0.130 |
Why?
|
| Rotation | 1 | 2017 | 9 | 0.130 |
Why?
|
| Head Movements | 1 | 2017 | 4 | 0.130 |
Why?
|
| Mucopolysaccharidosis II | 1 | 2016 | 1 | 0.130 |
Why?
|
| Torsion Abnormality | 1 | 2016 | 3 | 0.130 |
Why?
|
| Microscopy | 1 | 2017 | 38 | 0.130 |
Why?
|
| Tertiary Care Centers | 1 | 2017 | 32 | 0.130 |
Why?
|
| Hepatocytes | 2 | 2015 | 88 | 0.130 |
Why?
|
| Osteotomy | 1 | 2017 | 25 | 0.130 |
Why?
|
| Triage | 1 | 2017 | 34 | 0.130 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 236 | 0.130 |
Why?
|
| Endovascular Procedures | 1 | 2017 | 74 | 0.130 |
Why?
|
| Glasgow Coma Scale | 1 | 2016 | 22 | 0.130 |
Why?
|
| Granuloma, Foreign-Body | 1 | 2016 | 1 | 0.130 |
Why?
|
| Hemifacial Spasm | 1 | 2016 | 2 | 0.130 |
Why?
|
| Polytetrafluoroethylene | 1 | 2016 | 8 | 0.130 |
Why?
|
| Quality of Life | 1 | 2020 | 521 | 0.120 |
Why?
|
| Accidental Falls | 1 | 2016 | 32 | 0.120 |
Why?
|
| Referral and Consultation | 1 | 2017 | 98 | 0.120 |
Why?
|
| Collagen | 1 | 2017 | 156 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 433 | 0.120 |
Why?
|
| Injury Severity Score | 1 | 2016 | 131 | 0.120 |
Why?
|
| Cerebral Hemorrhage | 1 | 2016 | 93 | 0.120 |
Why?
|
| Preoperative Care | 1 | 2016 | 81 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 536 | 0.120 |
Why?
|
| Vagus Nerve | 1 | 2016 | 106 | 0.120 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2015 | 5 | 0.120 |
Why?
|
| GTPase-Activating Proteins | 1 | 2015 | 17 | 0.120 |
Why?
|
| T-Lymphocytes | 2 | 2014 | 285 | 0.110 |
Why?
|
| Case-Control Studies | 1 | 2017 | 739 | 0.110 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2015 | 25 | 0.110 |
Why?
|
| Liver Regeneration | 1 | 2014 | 6 | 0.110 |
Why?
|
| Chordoma | 1 | 2014 | 9 | 0.110 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2014 | 9 | 0.110 |
Why?
|
| Interleukin-17 | 1 | 2014 | 52 | 0.110 |
Why?
|
| Time Factors | 4 | 2020 | 1613 | 0.100 |
Why?
|
| Cell Communication | 1 | 2013 | 68 | 0.100 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2012 | 20 | 0.100 |
Why?
|
| Inflammation Mediators | 1 | 2014 | 169 | 0.100 |
Why?
|
| Fellowships and Scholarships | 2 | 2022 | 40 | 0.090 |
Why?
|
| Fatty Liver | 1 | 2013 | 77 | 0.090 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2012 | 120 | 0.090 |
Why?
|
| Antigens, CD | 1 | 2012 | 140 | 0.090 |
Why?
|
| Membrane Glycoproteins | 1 | 2012 | 149 | 0.090 |
Why?
|
| Fatty Acids | 1 | 2013 | 220 | 0.090 |
Why?
|
| Disease Progression | 1 | 2013 | 477 | 0.090 |
Why?
|
| Cell Proliferation | 1 | 2014 | 825 | 0.080 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2012 | 146 | 0.080 |
Why?
|
| Lipids | 1 | 2012 | 218 | 0.080 |
Why?
|
| Tumor Burden | 2 | 2021 | 110 | 0.080 |
Why?
|
| Bias | 2 | 2020 | 42 | 0.080 |
Why?
|
| Cell Differentiation | 1 | 2013 | 427 | 0.080 |
Why?
|
| Phenotype | 3 | 2020 | 686 | 0.080 |
Why?
|
| Mice | 6 | 2015 | 4808 | 0.080 |
Why?
|
| Recurrence | 2 | 2020 | 326 | 0.080 |
Why?
|
| Evidence-Based Medicine | 2 | 2020 | 146 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 4 | 2015 | 1658 | 0.070 |
Why?
|
| Aging | 1 | 2016 | 1017 | 0.070 |
Why?
|
| Animals | 7 | 2019 | 10699 | 0.070 |
Why?
|
| Combined Modality Therapy | 2 | 2020 | 303 | 0.070 |
Why?
|
| Syndrome | 2 | 2017 | 79 | 0.070 |
Why?
|
| Risk Assessment | 2 | 2020 | 631 | 0.060 |
Why?
|
| Computed Tomography Angiography | 2 | 2017 | 24 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 995 | 0.060 |
Why?
|
| Age Factors | 2 | 2021 | 737 | 0.060 |
Why?
|
| Pancreatic Neoplasms | 1 | 2012 | 548 | 0.060 |
Why?
|
| Cells, Cultured | 3 | 2014 | 1022 | 0.060 |
Why?
|
| Coloring Agents | 1 | 2025 | 37 | 0.060 |
Why?
|
| Chemokine CCL2 | 2 | 2015 | 47 | 0.050 |
Why?
|
| Necrosis | 2 | 2015 | 85 | 0.050 |
Why?
|
| Pituitary Gland | 1 | 2023 | 53 | 0.050 |
Why?
|
| Nose | 1 | 2023 | 24 | 0.050 |
Why?
|
| alpha-Fetoproteins | 1 | 2023 | 18 | 0.050 |
Why?
|
| Chorionic Gonadotropin | 1 | 2023 | 22 | 0.050 |
Why?
|
| Interleukin-6 | 2 | 2015 | 198 | 0.050 |
Why?
|
| Interferon-gamma | 2 | 2014 | 108 | 0.050 |
Why?
|
| Sex Characteristics | 1 | 2024 | 173 | 0.050 |
Why?
|
| Journal Impact Factor | 1 | 2022 | 8 | 0.050 |
Why?
|
| B7-2 Antigen | 2 | 2013 | 8 | 0.050 |
Why?
|
| B7-1 Antigen | 2 | 2013 | 11 | 0.050 |
Why?
|
| Pons | 1 | 2022 | 7 | 0.050 |
Why?
|
| Replantation | 1 | 2022 | 7 | 0.050 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2022 | 36 | 0.050 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 2013 | 59 | 0.050 |
Why?
|
| Anastomosis, Surgical | 1 | 2022 | 38 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2015 | 251 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2013 | 98 | 0.050 |
Why?
|
| Health Expenditures | 1 | 2022 | 30 | 0.050 |
Why?
|
| Killer Cells, Natural | 2 | 2013 | 65 | 0.050 |
Why?
|
| Lymphocyte Activation | 2 | 2014 | 210 | 0.050 |
Why?
|
| Monitoring, Physiologic | 1 | 2022 | 58 | 0.050 |
Why?
|
| Inpatients | 1 | 2022 | 60 | 0.050 |
Why?
|
| Policy | 1 | 2021 | 14 | 0.050 |
Why?
|
| Myelography | 1 | 2021 | 8 | 0.040 |
Why?
|
| Reference Standards | 1 | 2021 | 57 | 0.040 |
Why?
|
| Frail Elderly | 1 | 2021 | 16 | 0.040 |
Why?
|
| Liver Cirrhosis | 1 | 2022 | 78 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2015 | 874 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 56 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2021 | 49 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 2022 | 148 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2021 | 84 | 0.040 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2021 | 37 | 0.040 |
Why?
|
| Information Dissemination | 1 | 2021 | 37 | 0.040 |
Why?
|
| Sphenoid Sinus | 1 | 2021 | 5 | 0.040 |
Why?
|
| Astrocytes | 1 | 2022 | 80 | 0.040 |
Why?
|
| Cohort Effect | 1 | 2021 | 3 | 0.040 |
Why?
|
| Salvage Therapy | 1 | 2021 | 37 | 0.040 |
Why?
|
| Elective Surgical Procedures | 1 | 2021 | 74 | 0.040 |
Why?
|
| Family Characteristics | 1 | 2021 | 47 | 0.040 |
Why?
|
| Eye Diseases | 1 | 2021 | 31 | 0.040 |
Why?
|
| Audiometry | 1 | 2020 | 5 | 0.040 |
Why?
|
| Guideline Adherence | 1 | 2021 | 95 | 0.040 |
Why?
|
| Rupture, Spontaneous | 1 | 2020 | 10 | 0.040 |
Why?
|
| Electroencephalography | 1 | 2022 | 143 | 0.040 |
Why?
|
| Neurologic Examination | 1 | 2020 | 22 | 0.040 |
Why?
|
| Mycobacterium avium Complex | 1 | 2020 | 3 | 0.040 |
Why?
|
| Depression | 1 | 2022 | 225 | 0.040 |
Why?
|
| Software | 1 | 2021 | 127 | 0.040 |
Why?
|
| Femoral Neoplasms | 1 | 2020 | 2 | 0.040 |
Why?
|
| Gene Rearrangement | 1 | 2020 | 15 | 0.040 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2020 | 10 | 0.040 |
Why?
|
| Population | 1 | 2020 | 3 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2021 | 98 | 0.040 |
Why?
|
| Minnesota | 1 | 2020 | 42 | 0.040 |
Why?
|
| Africa South of the Sahara | 1 | 2020 | 13 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2020 | 46 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 194 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2020 | 106 | 0.040 |
Why?
|
| Hearing | 1 | 2020 | 28 | 0.040 |
Why?
|
| Neoplasm, Residual | 1 | 2019 | 32 | 0.040 |
Why?
|
| Adipose Tissue | 1 | 2021 | 197 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2021 | 480 | 0.040 |
Why?
|
| Biomarkers, Tumor | 1 | 2023 | 415 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2019 | 93 | 0.040 |
Why?
|
| Brain Abscess | 1 | 2019 | 6 | 0.040 |
Why?
|
| Learning Curve | 1 | 2019 | 13 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2020 | 134 | 0.040 |
Why?
|
| Dissection | 1 | 2019 | 20 | 0.040 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2019 | 20 | 0.040 |
Why?
|
| Nasal Cavity | 1 | 2019 | 21 | 0.040 |
Why?
|
| Gene Deletion | 1 | 2019 | 120 | 0.040 |
Why?
|
| Positron-Emission Tomography | 1 | 2020 | 100 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2020 | 288 | 0.040 |
Why?
|
| Internet | 1 | 2020 | 126 | 0.040 |
Why?
|
| Femoral Vein | 1 | 2019 | 13 | 0.040 |
Why?
|
| Repressor Proteins | 1 | 2020 | 119 | 0.040 |
Why?
|
| Rodentia | 1 | 2019 | 14 | 0.040 |
Why?
|
| Survival Rate | 1 | 2019 | 432 | 0.040 |
Why?
|
| Femoral Artery | 1 | 2019 | 58 | 0.040 |
Why?
|
| Cavernous Sinus Thrombosis | 1 | 2018 | 1 | 0.040 |
Why?
|
| Education, Distance | 1 | 2018 | 18 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 485 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 524 | 0.040 |
Why?
|
| Education, Medical, Continuing | 1 | 2018 | 34 | 0.040 |
Why?
|
| Fluorescein | 1 | 2018 | 6 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2018 | 211 | 0.030 |
Why?
|
| Intraoperative Care | 1 | 2018 | 23 | 0.030 |
Why?
|
| Faculty, Medical | 1 | 2018 | 59 | 0.030 |
Why?
|
| Retreatment | 1 | 2017 | 13 | 0.030 |
Why?
|
| Critical Care | 1 | 2018 | 49 | 0.030 |
Why?
|
| Angiography | 1 | 2017 | 35 | 0.030 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2017 | 21 | 0.030 |
Why?
|
| Deglutition Disorders | 1 | 2017 | 24 | 0.030 |
Why?
|
| Pain Management | 1 | 2018 | 66 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2018 | 91 | 0.030 |
Why?
|
| Chromosomal Instability | 1 | 2017 | 21 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2017 | 36 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2017 | 75 | 0.030 |
Why?
|
| Multiple Myeloma | 1 | 2017 | 39 | 0.030 |
Why?
|
| Fluorescent Dyes | 1 | 2018 | 93 | 0.030 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2017 | 33 | 0.030 |
Why?
|
| Proton Therapy | 1 | 2017 | 29 | 0.030 |
Why?
|
| Hypertension | 1 | 2020 | 309 | 0.030 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2017 | 4 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2020 | 916 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2018 | 163 | 0.030 |
Why?
|
| Cerebral Ventricles | 1 | 2017 | 17 | 0.030 |
Why?
|
| Macrophages | 1 | 2020 | 305 | 0.030 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2017 | 9 | 0.030 |
Why?
|
| Gray Matter | 1 | 2017 | 24 | 0.030 |
Why?
|
| Cerebrum | 1 | 2017 | 14 | 0.030 |
Why?
|
| Urinary Incontinence | 1 | 2017 | 20 | 0.030 |
Why?
|
| Constriction, Pathologic | 1 | 2016 | 36 | 0.030 |
Why?
|
| Occipital Lobe | 1 | 2017 | 21 | 0.030 |
Why?
|
| Patient Selection | 1 | 2017 | 150 | 0.030 |
Why?
|
| Parietal Lobe | 1 | 2017 | 27 | 0.030 |
Why?
|
| Stents | 1 | 2017 | 121 | 0.030 |
Why?
|
| Radiation Injuries | 1 | 2017 | 52 | 0.030 |
Why?
|
| Sampling Studies | 1 | 2016 | 24 | 0.030 |
Why?
|
| Glasgow Outcome Scale | 1 | 2016 | 4 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2016 | 48 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2016 | 50 | 0.030 |
Why?
|
| Biomarkers | 1 | 2019 | 777 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 76 | 0.030 |
Why?
|
| Smoking | 1 | 2020 | 478 | 0.030 |
Why?
|
| Length of Stay | 1 | 2017 | 245 | 0.030 |
Why?
|
| Concanavalin A | 1 | 2015 | 5 | 0.030 |
Why?
|
| Caspase 8 | 1 | 2015 | 10 | 0.030 |
Why?
|
| Rats | 1 | 2019 | 1588 | 0.030 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2015 | 16 | 0.030 |
Why?
|
| Acetaminophen | 1 | 2015 | 11 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 465 | 0.030 |
Why?
|
| Smoking Cessation | 1 | 2020 | 421 | 0.030 |
Why?
|
| Chemokine CCL20 | 1 | 2014 | 7 | 0.030 |
Why?
|
| Hepatectomy | 1 | 2014 | 26 | 0.030 |
Why?
|
| Lectins, C-Type | 1 | 2014 | 44 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2015 | 292 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2015 | 255 | 0.030 |
Why?
|
| Toll-Like Receptors | 1 | 2013 | 22 | 0.030 |
Why?
|
| Cyclin B1 | 1 | 2013 | 7 | 0.030 |
Why?
|
| Genes, MHC Class II | 1 | 2013 | 10 | 0.030 |
Why?
|
| Kupffer Cells | 1 | 2013 | 11 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2013 | 26 | 0.020 |
Why?
|
| Interleukin-12 | 1 | 2013 | 19 | 0.020 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2013 | 29 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2013 | 58 | 0.020 |
Why?
|
| PPAR gamma | 1 | 2013 | 29 | 0.020 |
Why?
|
| Interleukins | 1 | 2014 | 112 | 0.020 |
Why?
|
| bcl-X Protein | 1 | 2013 | 35 | 0.020 |
Why?
|
| Genotype | 1 | 2014 | 461 | 0.020 |
Why?
|
| Endoplasmic Reticulum | 1 | 2013 | 80 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2012 | 58 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2013 | 82 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2013 | 278 | 0.020 |
Why?
|
| Leukocyte Common Antigens | 1 | 2012 | 17 | 0.020 |
Why?
|
| CD40 Antigens | 1 | 2012 | 14 | 0.020 |
Why?
|
| CD11b Antigen | 1 | 2012 | 42 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2013 | 112 | 0.020 |
Why?
|
| Adipogenesis | 1 | 2012 | 27 | 0.020 |
Why?
|
| Antigens, CD1d | 1 | 2012 | 45 | 0.020 |
Why?
|
| Neutrophils | 1 | 2013 | 185 | 0.020 |
Why?
|
| Immune Tolerance | 1 | 2012 | 52 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2012 | 95 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2013 | 157 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2012 | 47 | 0.020 |
Why?
|
| Natural Killer T-Cells | 1 | 2012 | 55 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2012 | 152 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2012 | 231 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2012 | 472 | 0.020 |
Why?
|
| Inflammation | 1 | 2012 | 668 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2014 | 1469 | 0.020 |
Why?
|